enGene

enGene is a clinical-stage biotech company aiming to mainstream non-viral, gene-based immunotherapies for diseases of high unmet need, like #NMIBC.

[enGene @engene_inc]

Today, we reported our full year 2025 financial results, reflecting continued progress in advancing non-viral genetic medicine.

Read the full update: https://t.co/TlhFandPXi

[enGene @engene_inc]

Exciting news: our non-viral gene therapy for #NMIBC, has been accepted into the FDA’s CDRP Program. The Program is designed to strengthen our engagement with the FDA on CMC requirements and supports our preparations for a future planned BLA submission. https://t.co/bPKSnXEtAD

[enGene @engene_inc]

Today we’re encouraged by new preliminary results from the LEGEND trial pivotal cohort evaluating our non-viral gene therapy in non-muscle invasive bladder cancer (NMIBC), which demonstrated improved complete response rates. View the press release: https://t.co/YhbIe5XRRl

[enGene @engene_inc]

We’re proud to be recognized as a @biospace 2026 Best Places to Work. This recognition highlights our mission-driven culture & innovation in non-viral genetic medicines for urological cancers. Learn about this achievement: https://t.co/etV1bGTKzs #bestworkplaces

[enGene @engene_inc]

Hear from @KHubertChan, MD, MPH, our Executive Director & Urology Clinical Lead, on Pearls & Perspectives with @AmyPearlman1, MD! She discusses the challenges for high-risk NMIBC patients who fail BCG and our LEGEND trial.

Listen here: https://t.co/7rtDjtJ91q

[enGene @engene_inc]

We’re proud to sponsor & attend @IBCN1997 Annual Meeting, @UrologyUS’s Bladder & Kidney Cancer Academy and @JADPRO Live events this year.

Swipe for conference details and connect with our team in person to learn more about our investigational, non-viral gene therapy for #NMIBC.

[enGene @engene_inc]

enGene is excited for the 3️⃣ upcoming @AmerUrological meetings, where we will be highlighting encore data from our LEGEND trial, evaluating our investigational, non-viral gene therapy for patients with #NMIBC.

See below for meeting details!

[enGene @engene_inc]

Join us in welcoming this group of enGeneers! We’re thrilled to celebrate our new employees who have joined our team at a pivotal time, as we continue our mission to deliver innovative, non-viral, genetic medicine to improve the lives of people with urological cancers.

[enGene @engene_inc]

Join us in welcoming Hussein Sweiti, MD, MSc, as our Chief Medical Officer!

With 15+ years of experience, we’re confident he will be a great addition to our team, especially as we advance our lead investigational candidate for patients with #NMIBC.

https://t.co/7YatZDW30J

[enGene @engene_inc]

Team enGene was proud to sponsor and attend the 15th annual Canada Walks for Bladder Cancer this #UAM25. Alongside 300+ participants, our Canadian team was proud to show up strong to raise funds with the goal of improving outcomes for every bladder cancer patient. #BCCWalk

[enGene @engene_inc]

Will you be at the South Central Section or Mid-Atlantic Section of the @AmerUrological? Tune into one of several presentations from our team as we highlight the results from our ongoing LEGEND trial in patients with non-muscle invasive bladder cancer (#NMIBC).

[enGene @engene_inc]

This week, we announced our Q3 financial results and corporate updates.

Read the full update here: https://t.co/tfzBdMWWtQ

[enGene @engene_inc]

This week, our Co-Founder & Chief Scientific Officer, Anthony Cheung, PhD, will be presenting at #NanoThera2025. Alongside leading minds in gene therapy, he will share enGene’s unique non-viral approach—one we believe can help shape the future of care in urological cancers.

[enGene @engene_inc]

Today, Mark Preston, MD, MPH will be delivering two poster presentations at the New England Section of the @AmerUrological.

Attend the sessions or visit our exhibit booth to learn more about our novel, investigational, non-viral, gene therapy for patients with #NMIBC.

[enGene @engene_inc]

#BreakingNews: Target enrollment has been achieved in the pivotal cohort of the LEGEND trial for our investigational non-viral gene therapy in #NMIBC.

Full details here: https://t.co/Mv0Xp0k2ZM

[enGene @engene_inc]

Next month, we will be presenting at three investor conferences to deliver previously disclosed information about our novel, investigational, non-viral, gene therapy for patients with #NMIBC.

Full presentation details are available here: https://t.co/mnud1os7lZ

[enGene @engene_inc]

We are proud to sponsor and attend the @IBCG_BladderCA Annual Retreat (#IBCG) this weekend.

Alongside fellow leaders in bladder cancer, we will join discussions on biomarkers and IBCG-BTx, sharing background on our novel, investigational, non-viral, gene therapy for #NMIBC.

[enGene @engene_inc]

We were proud to sponsor and attend the @BladderCancerUS Think Tank during the organization’s 20th year of driving impact. Our team was honored to contribute to conversations that aim to improve quality of life for those impacted by bladder cancer.

[enGene @engene_inc]

Our CEO, Ron Cooper, is back on @biztv’s The Big Biz Show, discussing the latest developments at enGene and the significance of receiving the FDA’s RMAT designation for our investigational non-viral gene therapy, and what it means for the future of this disease.

[enGene @engene_inc]

We are proud to announce three promotions on our leadership team, and welcome three new members to our Board of Directors, all appointed to position our team for long-term growth at this pivotal time.

Read the full announcement: https://t.co/KDTywzmMH6